A Study of IPL344 in the Treatment of ALS Patients
Status:
Recruiting
Trial end date:
2022-08-15
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, phase 1/2a study, dose escalation, to evaluate
tolerability, safety, and PK of I.V. administered IPL344 in participants with Amyotrophic
Lateral Sclerosis (ALS).